FLT3 and acute myeloid leukemia: In most parts of the world, the current first-line standard-of-care therapy for younger patients with FLT3-mutant AML is cytarabine and an anthracycline combined with a FLT3 inhibitor (midostaurin or quizartinib), whereas older patients now usually receive venetoclax with azacitidine.10